Michael W. Weiner, United States of America
University of California San Francisco (UCSF) RadiologyModerator of 1 Session
Presenter of 3 Presentations
VALIDATING PLASMA TESTS FOR AMYLOID, TAU, AND NEURODEGENERATION USING THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI): PLASMA SAMPLES ARE AVAILABLE UPON REQUEST
Abstract
Abstract Body
Plasma assays for amyloid beta, phosphorylated tau, neurofilament light and other markers are now the most innovative and exciting development in the field of diagnostics for Alzheimer’s Disease (AD). The Alzheimer’s Disease Neuroimaging Initiative is in an ideal position to help validate and compare these assays, because plasma samples have been banked on over 2,270 participants at each longitudinal visit. ADNI data on plasma assays will be discussed.
The goal of ADNI (see ADNI-info.org) has been to standardize and validate MRI and PET imaging and blood/CSF biomarkers for Alzheimer’s treatment trials. Overall, we have enrolled a total of 2,272 participants: Elders with mild cognitive impairment (MCI) (n=1043); Dementia (n=397); Normal Controls (n=518) and 301 Controls with cognitive complaints. Participants have annual clinical visits, neuropsychological assessments, MRI (structural, perfusion, diffusion-tensor and task-free, resting-state fMRI), FDG PET, both amyloid and tau PET, blood and urine, and CSF (abeta, tau, ptau and other analytes), and whole genome sequencing. All ADNI data is available to all scientists in the world, on USC/LONI/ADNI, without embargo. A major interest in the field is to identify predictors of future risk for cognitive decline, and ADNI provides the largest available data set for analyses of this type. Over 2,200 papers have been published on ADNI.
Plasma, DNA, RNA, RBC pellets, and CSF samples can be requested online at http://adni.loni.usc.edu/data-samples/access-data/
ADNI will validate diagnostic techniques, including the new plasma assays, which can be used for diagnosis, and to measure the effects of treatments which slow progression and prevent AD.